Oncology

Following remarkable patient outcomes, Moffitt Cancer Center is scaling its AI-driven virtual care, signaling a major shift in cancer support.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

With a new CCO and advanced T-Body™ platform, Invenra is shifting from R&D to aggressive commercialization. Can it dominate the multispecific antibody market?

A new collaboration between the digital health giant and a top cancer center aims to deliver expert insights to doctors worldwide, tackling a complex field.

The cancer center's prestigious FACT accreditation for bone marrow transplants brings world-class blood cancer treatment closer to home for patients in Georgia.

A new clinical trial is testing a device that uses electricity to deliver chemo directly into tumors, a strategy that could revolutionize treatment.

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

The 12th Annual Ride of Hope adds new challenging routes to honor Terry's legacy, channeling funds into cutting-edge precision cancer research.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Renowned cancer researcher Dr. Dario Altieri leaves a top CEO post to return to the lab at Jefferson, signaling a major shift in Philadelphia's science scene.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

Europe's top cancer center adopts an AI orchestration platform, aiming to cut wait times, boost efficiency, and reshape the patient journey.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

A $200,000 donation, part of a $1M commitment, funds vital cancer research and celebrates one young girl's triumphant journey to recovery.

With 10 partner-owned drugs in clinics, MindWalk leverages its decades of wet-lab success to prove its new AI platform is more than just hype.

Biotheryx's novel protein degrader, BTX-9341, shows impressive safety and efficacy in patients who have progressed on standard therapies.